11-1-1997

The Progression of β-amyloid Deposition in the Frontal Cortex of the Aged Canine

Takao Satou
Kinki University

Brian J. Cummings
University of California - Irvine

Elizabeth Head
University of Toronto

Kristy A. Nielson
Marquette University, kristy.nielson@marquette.edu

Fletcher F. Hahn
Inhalation and Toxicology Research Institute

See next page for additional authors


Kristy Nielson was affiliated with the University of California - Irvine at time of publication.
The Progression of β-amyloid Deposition In The Frontal Cortex Of The Aged Canine

Takao Satoua
Second Department of Pathology,
Kinki University School of Medicine,
Osaka, Japan

Brian J. Cummings
Laboratories for Molecular Neuroscience, McLean Hospital,
Belmont, MA

Elizabeth Head
Department of Psychology, University of Toronto,
Toronto, Ont., Canada

Kristy A. Nielson
Institute for Brain Aging and Dementia, University of California,
Irvine, CA

Fletcher F. Hahn
Inhalation and Toxicology Research Institute,
Albuquerque, NM

Norton W. Milgram
Department of Psychology, University of Toronto,
Toronto, Ont., Canada
Abstract: Brains from 41 aged canines (≥10 years of age) were examined immunohistochemically to characterize the laminar distribution and age-related progression of β-amyloid (Aβ) in frontal cortex. We classified the Aβ patterns into four distinct types. Type I was characterized by small, faint deposits of Aβ in deep cortical layers. Type II consisted of diffuse deposits of Aβ mainly in layers V and VI. Type III had both dense plaques in superficial layers, and diffuse deposits in deep layers. Finally, Type IV had solely dense plaques throughout all layers of cortex. We compared the Aβ distribution pattern between the Old canines (10–15 years, n=22) and the Very Old canines (>15 years, n=19). The Old group primarily had negative staining, or Type I and Type II patterns of amyloid deposition (73%). Conversely, the Very Old group had predominantly Types II, III and IV deposits (89.5%), a difference that was significant (P<0.05). We suggest that Aβ deposition in canine frontal cortex is a progressive age-related process beginning with diffuse deposits in the deep cortical layers followed by the development of deposits in outer layers. In support of this hypothesis, the deeper layer diffuse plaques in the Very Old group of dogs also contain the largest proportion of β-amyloid with an isomerized aspartic acid residue at position 7, indicating that these deposits had been present for some time. We also observed fiber-like Aβ immunoreactivity within regions of diffuse Aβ deposits. These fibers appeared to be degenerating neurites, which were negative for hyperphosphorylated tau. Therefore, these fibers may represent a very early
form of neuritic change that precede tau hyperphosphorylation or develop by an alternative pathway.

**Keywords**: Diffuse plaque, Plaque type, Isoaspartate β-amyloid, Aging, Alzheimer's, Animal model, Beagle dog lifespan

## 1. Introduction

The classical neuropathological hallmarks of Alzheimer's disease (AD) are the progressive accumulation of extracellular β-amyloid (Aβ) within the parenchyma that form senile plaques, and intraneuronal cytoskeletal changes, which result in neurofibrillary tangles (NFTs). It has become clear that different plaque subtypes are present within the brains of aged non-demented individuals and AD patients. These plaque subtypes appear to progress through specific, identifiable stages beginning with diffuse, non-β-pleated structures followed by primitive plaques and then neuritic plaques, which are thioflavine- and Congo-red-positive. Characterizing the development of these lesions and their relation to NFTs is critical to understanding the pathogenesis of AD. However, the study of these processes is exceptionally difficult using human tissue because they occur over the course of years.

Previously, we suggested that the aged canine is a model system particularly well-suited to the investigation of the initial stages of plaque formation. The aged canine brain contains predominantly diffuse plaques. Furthermore, the incidence of plaque formation in the aged canine population is relatively high, without showing the classical feature of neurofibrillary tangle formation. Thus, this model may be useful for delineating the mechanisms involved in the initial stages of Aβ deposition and for studying the processes that promote plaque development into degenerative loci in the absence of tangles. Such an animal model is necessary, since it is difficult to study early AD pathology in the human brain due to the reserve capacity of the brain to absorb damage, and the rarity of early-stage autopsy tissue.

In addition to early neuropathological changes being present in many aged canine brains, it has been reported that canines experience age-related cognitive dysfunction. Aged canines are impaired on a variety of tasks, including delayed non-matching-to-sample recognition learning and spatial learning. Further, it has been reported that
various kinds of cognitive dysfunction in the aged canine correlate with the extent of Aβ deposition in hippocampus and frontal cortex. According to the research literature, study of the aged canine brain may also aid in our understanding of the morphological and cognitive changes that occur in aging.

It is generally assumed that NFTs and Aβ deposits in the human brain are not distributed randomly, but rather they have a characteristic regional and laminar pattern. The research literature regarding the laminar distribution of senile plaques in AD brain, however, is less than definitive. For example, Braak et al. reported that neuritic plaques are predominantly found in layers II and III of occipital isocortex, while Lewis and co-workers reported that neuritic plaques are most numerous in layers III and IV of the visual and auditory cortices. In fact, several investigators suggest that plaques are more common in the superficial cortical layers compared with deeper layers, while others suggest just the opposite. The apparent variability in the laminar specificity of plaque distribution in AD may be due in part to the variability in the disease stage of the cases examined in each study. As a result, characterizing the laminar distribution of Aβ deposits with advancing age in the canine cortex could help to clarify the distribution and progression of Aβ in AD brain.

Therefore, in the present study we sought to characterize the distribution and progression of pathological changes in AD by use of an animal model of senile plaque formation. Specifically, we sought to clarify the laminar distribution of Aβ within the frontal cortex of aged canines and to delineate the progression of Aβ deposition over time using Aβ immunocytochemistry and a large sample of aged canines. Because one consequence of amyloid deposition over a long period of time is the spontaneous isomerization of aspartic acid residues present at positions 1 and 7 of the β-amyloid peptide, we also used an affinity purified antibody specific for the isomerized form of β-amyloid to further investigate a progression hypothesis. We chose frontal cortex because it has been suggested that the distribution of Aβ is more consistent in frontal cortex than in the hippocampus, based on analyses of human brain.
2. Materials and methods

Thirty-two of the 41 animals in the study were beagles from the Inhalation Toxicology Research Institute's (ITRI) animal colony in Albuquerque, New Mexico. There were 27 females and 5 males. The age of these dogs ranged from 10.4 to 17.7 years at death (see Table 1). These dogs were part of a study designed to evaluate the health effects of the monoamine oxidase inhibitor l-deprenyl on young adult and aged beagles. Thus, they were treated with l-deprenyl (1 mg/kg/day) or placebo once a day for approximately 2 years 10 months. The time between cessation of treatment varied from 0 days to 101 days, depending on the cause of death (i.e. unplanned death, euthanasia due to disease, or planned sacrifice). The dogs were housed in kennel buildings with indoor and outdoor runs. They were fed a dry kibble (Wayne Mini Lab Dog Diet 8759, Teklad Laboratory Diets, Madison, WI) once a day over their life span.

Table 1. Descriptive data (mean±S.E.M., frequencies) on the groups of canines

<table>
<thead>
<tr>
<th>Group</th>
<th>Sex</th>
<th>Age (years)</th>
<th>Breed</th>
<th>Treatment a</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total (41)</td>
<td>6 M, 35 F</td>
<td>14.2±0.4</td>
<td>32 B1, 5 B2, 4 P</td>
<td>19 yes, 22 no</td>
</tr>
<tr>
<td>Old: 10–15 years (22)</td>
<td>2 M, 20 F</td>
<td>12.5±0.4</td>
<td>13 B1, 5 B2, 4 P</td>
<td>7 yes, 15 no</td>
</tr>
<tr>
<td>Very Old: &gt;15 years (19)</td>
<td>4 M, 15 F</td>
<td>16.2±0.2</td>
<td>19 B1, 0 B2, 0 P</td>
<td>12 yes, 7 no</td>
</tr>
</tbody>
</table>

aTreated with a monoamine oxidase inhibitor (l-deprenyl, 1 mg/kg/day; B1 only), others given placebo (B2) or not included in study (P).
bB1, ITRI beagle; B2, Marshall Farms beagle; P, pound dog (mongrel).

There were also five beagles born and raised at Marshall Farms in NY and four pound mongrels included in the study (Table 1). Two were male and seven (including all five beagles) were female, with ages ranging from 10.0 to 12.3 years. The age of the four pound dogs was based on available records and dentition.

The ITRI beagles were born and raised in the ITRI dog colony. The breeding program was a random, generation type system designed to maintain a gene pool as broad as possible. The members of each breeding generation were selected randomly from the available population, with restrictions placed only on sibling and half-sibling matings, and exclusion of dogs with EEG tracings suggestive of epilepsy.2
The dogs were observed daily by the animal technicians and were treated for all detected injuries and illnesses by the veterinary staff using standard accepted treatments. Dogs that showed signs of pain or anxiety that could not be controlled with medication were euthanized. Some of the dogs were euthanized as a planned schedule. All dogs that died or were euthanized were necropsied as soon as possible and all major organs were examined. Major organs and all lesions found were sampled for histopathology. A cause of death and other significant diseases for each dog were determined from the clinical records and pathology information.

In addition to the dogs included in this study, there were 398 control dogs that have been cared for in the colony for their entire life span. These dogs were used to estimate the life span of the laboratory beagle. The survival of this population was determined using a life-table method of analysis. The BMDP1 L Life Tables and Survival Functions statistical software package was used for this analysis. The cumulative survival is shown in Fig. 1. The median survival time was 13.7 years for the males and 13.6 years for the females. The survival times were not significantly different as demonstrated by the log-rank test.
Fig. 1. The cumulative survival curves for male and female control dogs (n=398) at the Inhalation Toxicology Research Institute. The median survival times of 13.7 years for males and 13.6 years for females were not significantly different (log-rank test).

Coronal brain sections (1 cm thick) were fixed in 4% paraformaldehyde for 2 days and held in 10% neutral buffered formalin at post-mortem. Dorsolateral frontal cortex was sectioned free-floating (50 μm) using a Vibratome. The sections were pretreated with 70% formic acid for 5 min and incubated with an affinity purified β-amyloid antibody (Aβ42, 1:1000) or an affinity purified antibody directed against isomerized β-amyloid (isoAsp7, 1:1050) using standard immune-histochemical procedures. Aβ42 is a rabbit polyclonal antibody against synthetic Aβ1–42 amyloid peptide. It preferentially recognizes full-length Aβ on Western blots and does not cross-react with native amyloid precursor protein (APP) in tissue or on Western blots. IsoAsp is a rabbit polyclonal antibody raised against synthetic Aβ1–15 with isoaspartic acid substituted for the aspartic acid.
A 16-amino-acid peptide of Aβ1–15 was synthesized (C. Glabe, UCI) containing isoAsp at residue 7 and a cysteine at residue 16 (the carboxy terminus). 500 μl at 2 mg/ml (0.976 μl) of this peptide was mixed with 200 μl reconstituted Pierce Maleimide Activated Keyhole Limpet Hemocyanin (KLH) (product #77106) at 10 mg/ml (0.7 μmol maleimide groups) and allowed to react for 2 h at room temperature. Aliquots of this immunogen (isoAsp7-KLH) were then frozen and stored at −70°C. For immunization, 375 μl isoAsp7-KLH was emulsified with 375 μl Freund's complete adjuvant (FCA) and injected (s.c.) into a New Zealand white rabbit. The rabbit was boosted with 150–200 μl (s.c.) twice at 2-week intervals with equal volumes of immunogen emulsified with Freund's incomplete adjuvant (FIA). One week after the first boost and 1 and 2 weeks after the second boost the rabbit was bled, screened for the presence of isoAsp7-specific antibodies, and rabbit IgG from three pooled bleeds was purified from serum using the octanoic acid/ammonium sulfate method. Aβ antibodies not specific for isoAsp7 were depleted from rabbit IgG using non-isomerized Aβ1–40 conjugated to Reacti-Gel Column (Pierce product #20259) three times. Antibodies specific for Aβ IsoAsp7 were then affinity purified from the rabbit IgG using the antigenic peptide containing isoAsp7 conjugated to Sulfolink coupling gel (Pierce product #20401). The eluted antibodies were then rerun over non-isomerized Aβ1-40 Recti-Gel Column to remove any remaining antibodies not specific for Aβ isoAsp7. The absence of Aβ1-40 cross-reactivity in the affinity purified anti-isoAsp7 antibodies was verified by an indirect detection ELISA.

After immunostaining, tissue sections were lightly Nissl counterstained to identify the cell layers. After dehydration in a graded series of alcohols and penetration with Histoclear (National Diagnostics, Atlanta, GA), sections were coverslipped with DePex (BDH Laboratory Supplies, Poole, UK). All sections were observed by light microscopy. In control experiments, we omitted the primary antibody or used normal rabbit serum instead of the primary antibody as negative controls. These tests resulted in no staining in the tissue sections.

To confirm degenerative nerve fibers, we double-labeled for Aβ42 and abnormally phosphorylated tau via PHF-1 (monoclonal antibody raised in mouse and kindly provided by Dr. S. Greenberg; 1:200) or SMI-311 (Sternberg Monoclonals, Baltimore, MD; 1:600).
Following Aβ42 staining and reaction with diaminobenzidine (DAB), the tissues were incubated in a second primary antibody overnight and then rinsed and incubated for 1.5 h in CY3-conjugated anti-mouse immunoglobulin G (IgG) (Jackson ImmunoResearch, 1:200). Sections were then washed in phosphate-buffered saline and mounted on gelatin-subbed slides with Vectashield (Vector Labs, CA).

3. Results

We observed Aβ deposition in nearly all of the aged canines examined (95%). While examining Aβ deposition in more than 100 animals over the past few years, we have noted that there appear to be several distinct patterns of Aβ deposition with possible intermediate stages. In some animals, large Aβ-immunopositive plaques are present within the superficial layers of cortex. In other animals, a diffuse cloud of Aβ deposition appears to have spread throughout the deep layers of cortex. This diffuse zone of Aβ often measures several millimeters. Based on these observations, we classified the morphological patterns of Aβ deposition observed in the aged canine brains in the present study into four subtypes. These subtypes are depicted in diagrammatic form in Fig. 2 and shown photographically in Fig. 3.

Fig. 2. Diagrammatic representation of the predominant patterns of Aβ deposition found in the frontal cortex of aged canines. The relative regions of each cortical layer are indicated in the left margin.
Fig. 3. Representative photomicrographs (×10) of each of the four patterns of Aβ deposition found in the frontal cortex of aged canines. Type I is shown in A, type II in B, type III in C and type IV in D. Two of the 41 canines exhibited no Aβ immunoreactivity. The remaining 39 animals were classified according to predominant Aβ pattern while blind to the experimental variables (e.g. age, sex, pharmacological treatment or breed).

3.1. Type I

Aβ deposition was light in density, small in size (less than 180 μm in diameter), and round in shape. These deposits were primarily restricted to layers V and VI and had obscure boundaries. These Aβ-positive plaques were usually isolated and few in number (Fig. 2, Fig. 3). The Type I pattern also contained fine fiber-like Aβ deposits around neurons (see Fig. 4).
Fig. 4. A: photomicrograph (×100) showing fine fiber-like Aβ immunoreactivity found in Type I Aβ deposition in the deep layers (V, VI) of canine frontal cortex. B: photomicrograph (100×) of Aβ-immunopositive tortuous fiber-like structures within the diffuse Aβ-immunoreactive zone of Type II Aβ deposition in canine frontal cortex. These fibers were PHF-I negative.

3.2. Type II

Aβ deposition was diffuse, cloud-like, and located primarily within the deep layers of cortex (V and VI). These Aβ deposits typically had obscure boundaries and a conspicuous tendency to fuse together. The deposits usually extended horizontally for several millimeters, but sometimes they also extended superficially to layers IV and III, and occasionally even to layer II. Aβ-Immunopositive tortuous fiber-like structures were also observed within the diffuse Aβ-immunoreactive zone, especially in the deeper layers (see Figs. 3 and 4).
3.3. Type III

Aβ deposition consisted of dense, round Aβ-positive plaques similar in morphological appearance to human senile plaques. They were usually less than 120 μm in diameter, but some exceeded 200 μm. This type of Aβ deposit displayed fairly distinct superficial boundaries within layers I through III. Type III deposition was also accompanied by a deeper cloud-like diffuse Aβ deposit comparable to that seen in Type II Aβ deposition (see Fig. 2, Fig. 3).

3.4. Type IV

Aβ deposition consisted of dense, round Aβ positive plaques throughout all layers of frontal cortex, rather than being restricted to layers I-III as in Type III. Type IV deposition, which was more rare than Type III, also lacked the diffuse Aβ ‘cloud’ in the deep cortical layers seen in Type III (see Fig. 2, Fig. 3).

While blinded to the experimental conditions, the predominant type of Aβ deposition present was classified for each animal. We then compared the distribution of Aβ subtypes between the Old group, which was composed of 10- to 15-year old canines (n=22), and the Very Old group, which was composed of canines older than 15 years (n=19).

Nearly 10% of the animals in the Old group displayed no Aβ-immunoreactivity, with Aβ Types I and II most commonly found in this group. Indeed, these three Aβ patterns (negative, I and II) characterized 73% of the canines between the ages of 10 and 15 years (see Table 2). Conversely, all of the Very Old canines exhibited some Aβ deposition. Types II, III and IV characterized 89.5% of the Very Old group. Graphical representation revealed that there is a shift in the deposition pattern to the right with advancing age, such that Types I and II in the 10–15-year-old dogs gave way to Types III and IV in the dogs older than 15 years (see Fig. 5). Comparison of the Old and Very Old groups by Mann–Whitney U analysis demonstrated a statistically significant difference between the deposition patterns (U=134.5, z=−2.04, P<0.05). There were no significant effects of tissue source, sex, breed, or monoamine oxidase inhibitor treatment on Aβ type. To
validate these results, Aβ type and age were submitted to simple and multiple regression models. Age was a significant predictor of Aβ deposition type ($r=0.43, P=0.005$), while breed, sex, and monoamine oxidase inhibitor treatment were not significant predictors.

### Table 2. Proportion of canine cases by age group exhibiting each of the patterns of Aβ deposition

<table>
<thead>
<tr>
<th>Dog age group</th>
<th>No Aβ</th>
<th>Type I</th>
<th>Type II</th>
<th>Type III</th>
<th>Type IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>10–15 years</td>
<td>9.1% (2)</td>
<td>22.7% (5)</td>
<td>40.9% (9)</td>
<td>22.7% (5)</td>
<td>4.6% (1)</td>
</tr>
<tr>
<td>&gt;15 years</td>
<td>0.0% (0)</td>
<td>10.5% (2)</td>
<td>36.8% (7)</td>
<td>36.8% (7)</td>
<td>15.9% (3)</td>
</tr>
</tbody>
</table>

Raw numbers of cases are in parentheses.

Fig. 5. Histogram depicting the change in proportion of Aβ deposition type between canines in the Old group (10–15 years) and the Very Old group (>15 years). There was a clear shift to the right, toward Types III and IV, in the Very Old group.

If, as suggested by our observations, deeper layer plaques are deposited before more superficial layers, then a marker of amyloid ‘age’ should be more prevalent in the deeper layers. β-Amyloid contains several aspartate residues that, over time, will isomerize to isoaspartate and could be detected with an antibody specific to β-amyloid containing isoaspartate. Accordingly, an antibody was raised to β-amyloid where an isoaspartate was substituted for aspartate at position 7. The affinity purified antibody was found to be specific (see Section 2) and was used to determine if the presence of isoAsp7 β-amyloid was preferentially distributed to specific layers. Only a proportion of plaques labeled with β-amyloid are also labeled with isoAsp7. In Type III and IV patterns of β-amyloid deposition, deep layer plaques, but few superficial layer plaques were positive for isoAsp7 (Fig. 6). This, along with the data on age-related changes,
supports the hypothesis that there is a sequence of plaque deposition in the canine frontal cortex which can be visualized as distinct patterns or `Types'.

![Image of photomicrographs showing deeper layer diffuse plaques containing Aβ typical of Type III (A) and Type IV (B) also containing isoAsp7 β-amyloid (C and D).](image)

**Fig. 6.** Representative photomicrographs showing that deeper layer diffuse plaques containing Aβ typical of Type III (A) and Type IV (B) also contain isoAsp7 β-amyloid (C and D).

The staining for PHF-1 was completely negative for cell bodies and fibers of neurons on the stained sections. SMI-311 was positive primarily in cell bodies of neurons but did not delineate Aβ-immunopositive fibers.
4. Discussion

We immunohistochemically examined frontal cortex tissue from 41 canines who were 10 or more years of age to characterize Aβ deposits and the differences in their distribution with age. We identified four distinct patterns of Aβ deposition: rare, punctate deposits in the deep layers; large, deep, cloud-like deposits; and dense, round plaques traversing all cortical layers. There was a clear change in the pattern of Aβ deposition with advancing age, which did not appear to relate to the source, sex, or pharmacological history of the animals. Aβ deposition within the Old animals (10–15 years old) consisted predominantly of small deposits within the deep cortical layers and diffuse cloud-like deposits, also predominantly restricted to deeper layers (i.e. Types I and II). Within this group, negative staining, Type I, and Type II patterns accounted for 73% of the cases, with Type II being the most prominent pattern (41%). In contrast, the Very Old group (>15 years old) exhibited Type III and IV patterns much more frequently. In fact, Types II, III and IV made up 90% of Aβ deposition in the Very Old cases, with Type III occurring as frequently as Type II (37% each).

Thus, with increasing age, there appeared to be a shift towards larger, denser Aβ deposits in the form of senile plaques, as well as greater deposition of Aβ in the superficial layers. Based on these observations, we hypothesize that the earliest deposition of Aβ occurs within the deep layers of frontal cortex (layers V and VI) in the canine. Over time, diffuse cloud-like extensions of Aβ also form in the deepest layers of cortex. Later, denser plaque-like deposits of Aβ form in the more superficial layers of cortex (i.e. II and III), and these deposits grow in size. The presence of deep layer diffuse plaques positive for isomerized aspartic acid residues also supports a progression hypothesis. Importantly, the median life expectancy of the canine population examined is just under 14 years (see Fig. 1) and yet Aβ deposition was commonly observed much earlier. Therefore, it appears that Aβ deposition begins in late middle age, rather than in the latest stages of life.

We also observed fiber-like Aβ immunostaining within the deep cortical layers. We have previously described these fibers as
neurofilament-positive and Aβ-positive fibers; they are similar in morphological appearance to neuropil threads, which are nearly always observed in the AD brain. Braak et al. have indicated that neuropil threads may densely fill a layer without the presence of NFTs (e.g. layer V of striate cortex). Since these neuropil threads are important components of AD-related pathology, efforts to elucidate the conditions responsible for their development and pattern of distribution are valuable. In the canine brain, however, NFT changes have not been observed. Similarly, we did not detect PHF-1 or SMI-311 immunoreactivity associated with Aβ-positive fibers in the present study. We suspect that the canine brain exhibits very early phosphorylation changes in nerve fibers, which cannot be detected with the antibodies that show tau pathology in AD brain. Alternatively, age-associated nerve fiber degeneration in the canine brain may be caused by a mechanism other than hyperphosphorylation of tau. For example, Migheli et al. argue that ubiquitin-positive fibers are present within the aged canine brain.

While it is clear that extensive Aβ deposition commonly occurs in the aged canine, the source of the Aβ found within the neuropil remains unknown. In a number of model systems, it has been confirmed that Aβ is secreted by neurons. Indeed, we often observe Aβ-filled neurons in the canine brain. In addition, Aβ is detectable in human cerebrospinal fluid. Therefore, there is likely to be an evacuation mechanism for Aβ from the parenchyma to the ventricular system. Furthermore, it has been reported that APP is produced in the cell body of neurons and is carried by anterograde fast axonal flow to nerve endings and, at sites of amyloid deposition, is aberrantly processed into Aβ. This raises the possibility that either overproduction of APP and Aβ, abnormal axonal flow, or abnormal clearance of Aβ are the cause of Aβ deposition in the aged brain. It is also possible that more than one of these factors contributes to the problem.

Our observations of fiber-like Aβ staining within deep layers of frontal cortex and the diffuse deposits surrounding them in the neuropil (Fig. 4) are consistent with the suggestion that Aβ deposition is initiated at the nerve terminal. These Aβ-immunopositive fibers may therefore be an expression of early Aβ deposition originating in corticocortical projections from layers II and III to deeper layers.
Later in time, Aβ deposits may form around the cell bodies of these projecting neurons. Indeed, we observed that the dense round-shaped Aβ deposits in the Type III pattern were localized around the neurons in layers II and III. These results have important implications for the relationship between Aβ and nerve fiber degeneration in the aged canine. For example, it has been reported that axonal degeneration promotes abnormal accumulation of Aβ in the ascending gracile tract of the gracile axonal dystrophy mouse.17

There were remarkable similarities between the late-stage Aβ deposition patterns of aged canines and that in AD brain. First, Type III and IV canine plaques resembled the human senile plaques observed in AD brain, although other studies have shown that canine plaques did not exhibit β-pleated structure and they were larger than typical AD plaques.8 Second, Type III Aβ deposition demonstrated a laminar distribution, primarily in layers II and III. On the other hand, Type IV Aβ deposition, where canine plaques appeared even more similar in shape to human senile plaques, was scattered across all layers with no laminar specificity. This pattern was comparable to the irregular laminar distribution of plaques in AD brain.4

Our observations in the canine brain suggest that the process of Aβ deposition is multiphasic, exhibiting different morphological and laminar characteristics over time. Thus, the laminar distribution of senile plaques may become obscured in human brain as AD reaches advanced stages. Moreover, it has been reported that as the severity of dementia increases, the density of mature plaques generally increases, but that of primitive plaques decreases, such that there tends to be an overall decrease in total plaque density.25 This makes analysis of the distribution of Aβ deposition in AD brain complex, especially using general histological staining methods. Therefore, the interpretation of results from previous reports of Aβ distribution in AD brain may have been obscured by the inclusion of observations from patients at several different stages of AD pathology.

In this study, we found diffuse Aβ deposits in the deep layers of frontal cortex. This morphology has not been reported in aged human or AD brain. This phenomenon may be a very early event in the deposition of Aβ in frontal cortex, making it difficult to observe in human brain. Alternatively, it may be a pattern specific to the aged
canine. This issue remains to be clarified. As the aged canine model of Aβ deposition is further characterized and refined, it will certainly be important for testing hypotheses about Aβ deposition and plaque formation in human aging and AD.

Acknowledgements

We gratefully acknowledge the editorial assistance of Andrea Walencewicz Wasserman in manuscript preparation. This project was supported by Grants AG12694 (C.W.C., B.J.C., N.W.M.), AG00538 (C.W.C.), AG05716 (K.A.N.), and NIH N535144 (D.H.C.).

References


